Tuesday, May 27, 2014

The Motley Fool: Can Novartis AG Maintain Its Momentum?

Novartis (NYSE: NVS  ) has done better over the past six months than I thought it would back in December of 2013, as investors have liked what they've seen with the company's restructuring efforts and surprisingly positive clinical data on heart failure drug candidate LCZ696. In the "what have you done for me lately?" world of Wall Street, though, I do wonder whether Novartis has enough potential catalysts in hand to keep up a level of enthusiasm that frankly seems outsized relative to the valuation.

Read more here:
Can Novartis AG Maintain Its Momentum?

No comments: